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Abstract
Background: Coagulase negative staphylococcus (CONS) is the main cause of late-onset sepsis
in Neonatal Intensive Care Units (NICU). Although CONS rarely causes fulminant sepsis,
vancomycin is frequently used as empiric therapy. Indiscriminate use of vancomycin has been linked
to the emergence of vancomycin resistant organisms. The objective of this study was to compare
duration of CONS sepsis and mortality before and after implementation of a policy of selective
vancomycin use and compare use of vancomycin between the 2 time periods.
Methods: A retrospective study was conducted of infants ≥4 days old, experiencing signs of sepsis
with a first positive blood culture for CONS, during two 12-month periods. Late-onset sepsis was
treated empirically with vancomycin and gentamicin during period 1, and cloxacillin and gentamicin
during period 2. The confidence interval method was used to assess non-inferiority of the
outcomes between the two study groups.
Results: There were 45 episodes of CONS sepsis during period 1 and 37 during period 2.
Duration of sepsis was similar between periods (hazard ratio of 1.00, 95%CI: 0.64, 1.57). One death
during period 2 was possibly related to CONS sepsis versus none in period 1. Vancomycin was
used in 97.8% of episodes in period 1 versus 81.1% of episodes in period 2.
Conclusion: Although we failed to show non-inferiority of duration of sepsis in the cloxacillin and
gentamicin group compared to the vancomycin and gentamicin group, duration of sepsis was
clinically similar. Restricting vancomycin for confirmed cases of CONS sepsis resistant to oxacillin
appears effective and safe, and significantly reduces vancomycin use in the NICU.
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Background
Coagulase negative staphylococcus (CONS) is the main
cause of late-onset sepsis in neonatal intensive care units
(NICU) [1]. Although fulminant late-onset sepsis (death
occurring in less than 48 h) is usually due to gram-nega-
tive organisms, CONS may cause fulminant sepsis in
about 1% of cases [1]. Increasing resistance of CONS to β-
lactam antibiotics has prompted many NICUs to use van-
comycin for initial treatment of presumed late-onset sep-
sis.
The use of vancomycin is an important risk factor for the
emergence of vancomycin-resistant organisms, such as
vancomycin-resistant enterococcus, and vancomycin-
resistant Staphylococcus aureus [2-7]. These organisms can
cause serious, life-threatening infections, but therapeutic
options are limited. The possibility of developing an
infection that cannot be treated with available antibiotics
is a major public health concern. Restricting vancomycin
use is considered important in preventing the develop-
ment and spread of such organisms, and has been recom-
mended by the Hospital Infection Control Practices
Advisory Committee [8,9]. Critical care settings, such as
the NICU, provide an ideal environment for the develop-
ment and spread of resistant organisms due to the inten-
sity of antimicrobial use, the close proximity of
susceptible patients, and efficient vehicles of spread such
as the hands of healthcare personnel. Therefore, finding
effective alternatives to vancomycin for empiric therapy
for sepsis in the NICU population would be an important
achievement.
Several retrospective reviews suggest that restricting van-
comycin use to confirmed cases of CONS sepsis is not
associated with increased mortality or morbidity, even
when oxacillin resistance rates are high [1,10-13]. How-
ever, these studies are limited by incomplete susceptibility
data on the organism, and lack of a standard definition for
duration of sepsis. Furthermore, the impact of removing
the central venous catheter, if present, is not systemati-
cally accounted for, but can be a confounding factor in
evaluating outcome [14-16].
A cluster of S. aureus sepsis in our NICU in early 2000
prompted a change in our initial therapy for presumed
late-onset sepsis from vancomycin and gentamicin (non-
restricted policy) to cloxacillin and gentamicin (restricted
policy). In view of previous reports suggesting the proba-
ble safety of this practice, [1,10-13] and concerns about
the emergence of antibiotic-resistant strains, we have con-
tinued to use cloxacillin and gentamicin as initial therapy,
and to reserve vancomycin use for CONS sepsis with in-
vitro resistance to oxacillin.
The primary aim of this study was to compare the dura-
tion of sepsis in infants who received cloxacillin with
those who received vancomycin as empiric therapy for
late-onset CONS sepsis. We hypothesized that restricting
vancomycin use to oxacillin resistant organisms only, for
late onset sepsis in the NICU would not be inferior to a
non-restricted policy.
Methods
Study design
We conducted a retrospective chart review of infants with
a positive blood culture for CONS and clinical signs of
sepsis, treated with antibiotics during either of the two
study periods. The study periods were defined as January
1, 1999 through December 31, 1999 (period 1) and April
1, 2000 through March 31, 2001 (period 2). Initial ther-
apy for sepsis consisted of intravenous vancomycin (15–
20 mg/kg/dose) plus gentamicin (2.5 mg/kg/dose) during
period 1, and intravenous cloxacillin (50 mg/kg/dose)
plus gentamicin (2.5 mg/kg/dose) during period 2. The
new protocol for empiric therapy was implemented
between January and March 2000, and data from this
period are not included as practices were inconsistent.
During period 2, vancomycin could be used instead of
cloxacillin and gentamicin only if the organism was oxa-
cillin-resistant. The policy included stopping gentamicin
once the CONS susceptibility profile was available, and
the infant had clinically improved. The susceptibility pro-
file was typically available at 48 to 72 hours. Patients rou-
tinely had pre- and post-drug levels drawn with the 3rd
dose of vancomycin and gentamicin. Drug dose was
adjusted based on these results to ensure levels remained
therapeutic.
Study population
All infants 4 days of age or older (day of birth counting as
day 1) diagnosed with a first CONS sepsis in the NICU of
The Ottawa Hospital, General Campus (Ontario, Canada)
during the two study periods were eligible for this study.
CONS sepsis was defined as one positive blood culture for
CONS (within 48 hours of incubation) plus one or more
of the following signs of infection: lethargy, increased fre-
quency of apneic spells over baseline, temperature insta-
bility of more than 1 degree Celsius over 24 h, need for
intubation or increased ventilatory support, or poor per-
fusion requiring fluid boluses or inotropic support. Epi-
sodes were excluded as contaminants if they did not meet
these clinical criteria for CONS sepsis, or if blood culture
isolated either a second non-CONS organism or a second
CONS strain. Repeat episodes of CONS sepsis were
excluded.
The NICU of The Ottawa Hospital General Campus is a
regional tertiary perinatal care center. The hospital serves
a population of one million people, with 18 000 liveBMC Pediatrics 2005, 5:49 http://www.biomedcentral.com/1471-2431/5/49
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births per year. The NICU admits approximately 350
infants annually, 150 (43%) of whom weigh less than
1500 grams at birth. The rate of methicillin-resistant Sta-
phylococcus aureus (MRSA) in this facility is approximately
17 per 100 000 patient days. In the past 10 years, MRSA
has been isolated from only two NICU infants. In both
instances the isolate represented colonization, rather than
infection, and the incidences were not epidemiologically
linked. There have been no documented isolates of vanco-
mycin-resistant enterococcus, or vancomycin-resistant
Staphylococcus aureus in our NICU.
Laboratory methods
A single peripheral blood culture was obtained from each
infant in whom late-onset sepsis was suspected. The site of
venipuncture was prepared by cleansing the skin with an
antiseptic swab impregnated with 0.5% w/v chlorhexi-
dine gluconate and 70% v/v isopropyl alcohol in a circu-
lar motion, beginning at the site and working outward for
a 3–5 cm diameter. The site was allowed to dry for 60 sec-
onds and then 0.5 ml of blood was drawn using a 25G
butterfly needle. The blood was inserted into a blood cul-
ture vial (BacT/ALERT PF Pediatric bottle, BioMérieux
Inc., Durham, NC, USA). There was no standard protocol
for repeat of blood cultures. If the baby remained clini-
cally unwell, or if antibiotics were switched due to culture
insensitivity, cultures were routinely repeated prior to
changing or adding antibiotics. Cultures of catheter tips, if
removed, were not routinely obtained.
Coagulase-negative staphylococci were identified using
standard microbiological methods but were not further
speciated. Oxacillin and gentamicin susceptibilities were
determined by the disk diffusion method following the
National Committee for Clinical Laboratory Standards.
The interpretive criteria used for resistance have been
shown to correlate highly with the presence of the mecA
gene, which is the genetic determinant for oxacillin resist-
ance in staphylococci [17].
Outcomes
The primary outcome for the study was duration of sepsis,
defined as either the length of time from the first positive
blood culture for CONS until the first documented nega-
tive blood culture (in days), or the time to clinical recov-
ery (in days). Because we cannot be sure of either the exact
time of onset of sepsis, or of clinical recovery, duration of
sepsis can only be considered accurate to within one day.
If there was apparent clinical recovery, but persistently
positive blood cultures, duration of sepsis was defined as
time to negative blood culture. Clinical recovery was
defined as return to prior clinical status including resolu-
tion of lethargy and temperature instability, extubation if
previously non-ventilated, or return to previous level of
ventilatory support, the end of inotropic support, and the
same average daily number and quality of apneic spells as
before the onset of sepsis.
Secondary outcomes were mortality rate, within 14 days
of the first positive blood culture for CONS, duration of
sepsis with and without a central line, and vancomycin
use during the two study periods. Gentamicin susceptibil-
ity of the CONS strains implicated in each sepsis episode
was determined to account for the potential impact of
concurrent gentamicin use on the primary outcome.
The Ottawa Hospital Research Ethics Committee
approved this study.
Statistical analysis
Summary statistics were expressed as frequencies, or as the
mean ± standard deviation, median and range. Baseline
characteristics were compared between the two study
groups using Student's t-test and Fisher's exact test. Birth
weight, gestational age and age at onset of sepsis were not
normally distributed. Therefore, statistical comparisons
have been run on the log-transformed data. Length of
time between sepsis and antibiotics was compared using a
log-rank test. Use of vancomycin was compared using
Fisher's exact test.
Unlike traditional hypothesis testing approaches, where
the research hypothesis is that two interventions differ, in
a non-inferiority study the research hypothesis is that one
intervention is not clinically inferior to the other. This
requires the prior specification of a difference large
enough to clinically favour the standard intervention over
the study intervention. The study intervention is declared
non-inferior to the standard intervention when the confi-
dence interval contrasting them only covers values smaller
than this prespecified amount [18]. Differences in dura-
tion of sepsis, adjusted for lethargy, were measured using
the hazard ratio and its 95% confidence interval (CI), esti-
mated using Cox regression. Assuming that duration of
sepsis with the 1999 protocol (non-restricted vancomycin
use) was about 3 days [1,12], a clinically inferior duration
of sepsis was taken to be 4 days, corresponding to a mar-
gin of inferiority on the hazard ratio scale of 1.33. For the
secondary outcome, difference in proportion of mortality
was computed with its 95% CI estimated using the Wilson
score method [19]. The margin of non-inferiority was
taken to be a 1% difference in mortality.
Results
There were 54 positive CONS blood cultures in period 1
(1999) and 43 positive blood cultures in period 2 (2000–
2001). Six of these episodes (three in each period) did not
meet the clinical definition for CONS sepsis (two infants
had concomitant fungal or gram negative sepsis, two did
not receive antibiotics and two had no clinical sign of sep-BMC Pediatrics 2005, 5:49 http://www.biomedcentral.com/1471-2431/5/49
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sis) and were excluded as likely contaminants. Six cultures
in period one and three in period two were excluded
because they were second episodes of CONS sepsis. Base-
line characteristics of the excluded infants/episodes were
comparable to those of the included ones. Baseline char-
acteristics of the remaining 45 infants in period 1 and 37
infants in period 2 are presented in Table 1.
In period 1, 44 of the 45 episodes of CONS sepsis were
treated empirically with vancomycin and gentamicin. In
11 of these 44 episodes, antibiotics were switched to
cloxacillin when susceptibilities were available. Two of
the 44 infants were given a dose of ampicillin before van-
comycin was initiated. In the 45th episode, the infant
received ceftazidime and gentamicin, which was changed
to cloxacillin after identification of CONS. In period 2, 35
of the 37 episodes were treated empirically with cloxacil-
lin and gentamicin. In 28 of these 35 episodes, antibiotics
were changed to vancomycin when the CONS isolate was
determined to be resistant to oxacillin. In two episodes,
cloxacillin was continued despite resistance as the infant
had clinically improved. These two isolates were also
resistant to gentamicin, however the central line was
removed in one infant during the sepsis. Two episodes in
period 2 were treated empirically with vancomycin. In
one of these episodes the antibiotic coverage was switched
to cloxacillin when the organism was shown to be suscep-
tible to oxacillin.
Comparisons of the main outcomes are shown in Table 2.
The mean duration of sepsis was comparable between
study periods, 3.6 days (Range: 1 to 10 days) versus 3.4
days (Range: 1 to 12 days); although non-inferiority of a
restricted vancomycin policy could not be demonstrated
Table 1: Characteristics of Infants Treated for Coagulase-Negative Staphylococcus
Period 1: 1999 (No 
vancomycin restriction) 
(n = 45)
Period 2: 2000–2001 
(Vancomycin 
restriction) (n = 37)
Difference (95% CI) p-value
Baseline characteristics, median (range)
Birth weight, grams 890 (550, 1750) 966 (628, 3417) 39 (-69, 148) 0.269
Gestational age, weeks 27 (24, 31) 27 (24, 41) 0.0 (-1.0, 1.0) 0.337
Age at onset of sepsis, days 13 (4, 74) 10 (5, 23) -2 (-4, 1) 0.149
Characteristics at onset of sepsis, n (%)
Presence of a central 
venous line
18 (40.0) 21 (56.8) 16.8 (-4.8, 36.3) 0.183
Central venous line 
removal *
10/18 (55.6) 10/21 (47.6) 7.9 (-35.6, 21.7) 0.751
Receiving total parenteral 
nutrition
41 (91.1) 36 (97.3) 6.2 (-6.2, 18.2) 0.372
Prior antibiotics 43 (95.6) 33 (89.2) -6.4 (-20.6, 5.9) 0.402
Mean time between sepsis 
and prior antibiotics, days 
(sd)
6.4 (4.4) 4.7 (3.4) -1.7 (-3.5, 5.8) 0.053
Clinical signs of sepsis, n (%)
Lethargy 41(91.1) 25 (67.6) -23.5 (-40.5, -6.1) 0.011
Increased frequency of 
apneic spells
35 (77.8) 23 (62.1) -15.6 (-34.4, 4.1) 0.148
Temperature instability 23 (51.1) 17 (45.9) -5.2 (-25.6, 15.9) 0.664
Need for increased 
ventilatory support
9/12 (75.0) 15/16 (93.7) 18.8 (-8.6, 47.4) 0.285
Need for intubation in 
infants not on any 
ventilatory support
20/33 (60.6) 14/21 (66.7) 6.1 (-19.8, 29.4) 0.775
Poor perfusion requiring 
fluid boluses or inotropic 
support
15 (33.3) 11 (29.7) -3.6 (-22.7, 16.4) 0.814
Isolate resistant, n (%)
Cloxacillin 34 (75.5) 29 (78.4) 2.8 (-15.8, 20.4) 0.799
Gentamicin 30 (66.7) 26 (72.2) 3.6 (-16.4, 22.7) 0.635
Both cloxacillin and 
gentamicin
23 (51.1) 26 (72.2) 21.1 (-0.03, 39.6) 0.113
* Percentage based on infants with a central venous lineBMC Pediatrics 2005, 5:49 http://www.biomedcentral.com/1471-2431/5/49
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potentially due to insufficient sample size. In surviving
infants, duration of sepsis was documented as either the
length of time from the first positive blood culture for
CONS until the first documented negative blood culture
(14 episodes in period 1 and 16 episodes in period 2) or
as the length of time to return to previous clinical status
(31 episodes in period 1 and 17 episodes in period 2).
No infants died during the 14 days after positive CONS
blood culture during period 1, and four infants died dur-
ing this time in period 2. Three of these deaths were con-
sidered unrelated to sepsis. One infant was critically ill
with severe chronic lung disease and pulmonary intersti-
tial emphysema when she developed CONS sepsis. A deci-
sion was made to withdraw therapy based on poor lung
function. The other two infants had documented negative
blood cultures for CONS several days before their deaths,
which were felt to be due to underlying comorbidities.
One of these two infants developed an Escherichia coli sep-
sis 5 days into treatment for CONS, while treated with
vancomycin. The second infant died after therapy was
withdrawn because of worsening pulmonary interstitial
emphysema and lung blebs, recurrent pneumothorax and
grade II and IV intraventricular hemorrhages. One death
was considered possibly related to CONS sepsis. The
patient was 25 weeks gestation, born weighing 831 g, who
became sick at 2 weeks of age, with apneic spells, temper-
ature instability, poor perfusion and increased ventilator
requirements. He was started on cloxacillin and gen-
tamicin. The CONS strain in this case was resistant to both
oxacillin and gentamicin. Because of clinical deteriora-
tion, vancomycin was added to therapy before the suscep-
tibility results were available, however the infant died the
same day. An autopsy was not performed to confirm the
clinical impression of death due to CONS sepsis.
A total of 39 infants in the two periods had central venous
lines at the onset of sepsis (Table 1). When adjusted for
therapy protocol, and lethargy, duration of sepsis with a
line present was statistically longer than when no line was
present, 4.6 (3.3 sd) versus 2.6 (1.7 sd) days; p = 0.019.
Use of vancomycin for CONS sepsis decreased from 44
out of 45 episodes (97.8%) in period 1 to 30 out of 37 epi-
sodes (81.1%) in period 2 (p = 0.020). In total, in period
1 790 doses of vancomycin were given for CONS sepsis,
compared to 347 doses in period 2. Including CONS sep-
sis episodes, there were a total of 96 episodes of presumed
late-onset sepsis during period 1 and 102 episodes during
period 2. The majority of these episodes were culture neg-
ative and antibiotics were stopped. Included in the 198
episodes of presumed late-onset sepsis in both periods
were 17 episodes of sepsis with another organism {period
1:  Staphylococcus aureus (1),  Escherichia coli (2),  Entero-
bacter cloacae (2), Pseudomonas aeruginosa (1), Enterococcus
faecalis (1); period 2: Staphylococcus aureus (3), Escherichia
coli  (2),  Enterobacter cloacae (1),  Candida albicans (3),
Group A Streptococcus (1)}. Vancomycin was used in a
total of 82/96 (85.4%) episodes (1042 doses) in period 1
compared to 42/102 (41.2%) episodes (409 doses) in
period 2 (p < 0.001).
The majority of CONS strains were resistant to oxacillin,
gentamicin or both (Table 1). One isolate, in period 2,
failed to grow on susceptibility testing media for gen-
tamicin. In period 2, 29 isolates were resistant to oxacillin.
In 27 of these cases, antibiotics were switched to vanco-
mycin, however 14 (52%) of these 27 infants had clini-
cally improved from their sepsis before the start of
vancomycin: 10 had returned to their baseline clinical sta-
tus, 2 had a negative blood culture and 2 had both before
initiation of vancomycin. Two of these 14 CONS isolates
were sensitive to gentamicin, and another was taken from
an infant who had his central venous line removed after
the onset of sepsis but before the vancomycin was given.
The remaining 11 infants recovered with cloxacillin and
gentamicin while sensitivity testing indicated in-vitro
resistance to both oxacillin and gentamicin.
Discussion
This is one of the largest studies aimed primarily at com-
paring outcomes in neonates with CONS sepsis. Although
non-inferiority of a restricted vancomycin policy could
not be demonstrated (potentially due to insufficient sam-
ple size), the mean duration of sepsis among infants
treated with empiric cloxacillin and gentamicin was com-
parable to that among infants treated with empiric vanco-
mycin. Mortality was low in both groups of infants in this
study. There was one death in an infant treated with
empiric cloxacillin and gentamicin that may have been
Table 2: Outcome of Infants Treated for Coagulase-Negative Staphylococcus
Variables Period 1 1999 (No 
vancomycin restriction) 
(n = 45)
Period 2 2000–2001 
(Vancomycin 
restriction) (n = 37)
Hazard ratio 
(95 %CI)
Difference of % 
(95% CI)
Mean duration of sepsis, days (sd) 3.6 (2.5) 3.4 (3.0) 1.2 (0.8, 2.0)* N/A
Deaths due to CONS sepsis, n (%) 0 (0.0) 1 (2.7) N/A -2.7 (-13.8, 5.5)
14 day mortality, n (%) 0 (0.0) 4 (10.8) N/A -10.8 (-24.7, 0.6)
* Hazard ratio based on the Cox regression modelBMC Pediatrics 2005, 5:49 http://www.biomedcentral.com/1471-2431/5/49
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linked to CONS sepsis; however, insufficient clinical
information was available to establish causality.
These results are consistent with previously published
studies [1,10,11]. Karlowicz et al [1] reviewed all cases of
late-onset sepsis, including 277 episodes of CONS sepsis,
over a 10-year period in one institution. The number of
episodes, duration and mortality rates were similar
whether vancomycin and cefotaxime or cloxacillin and
gentamicin were used empirically. However, no informa-
tion regarding the presence or removal of a central venous
line, sensitivity data or details about baseline characteris-
tics of included infants were available, thus limiting gen-
eralizability. Matrai-Kovalskis et al [10] reviewed 127
episodes of positive blood cultures for CONS of which
only 22 were considered true sepsis. Clinical signs were
not part of the definition of sepsis. These episodes were
compared to 105 episodes selected randomly from a sam-
ple of 210 considered contaminants. Infants in both
groups were treated with ceftazidime+/- ampicillin or
cloxacillin; vancomycin was reserved for confirmed cases
of CONS. There was no difference in rates of recovery
between the groups, although three infants in the "con-
taminant" group died and several received a full antibiotic
course. Krediet et al [11] reviewed 66 cases of CONS sep-
sis, treated with cephalothin alone, vancomycin alone or
cephalothin then vancomycin once resistance to oxacillin
was confirmed. Mortality and duration of sepsis were sim-
ilar between the 3 groups, even though CONS was resist-
ant to oxacillin in 85% of cases. None of these studies
reported differences in death rates between groups; how-
ever, they were not powered for death as an outcome.
Although these data are reassuring, the limited sample
size in the present study does not permit the demonstra-
tion of non-inferiority in mortality between the two
patient groups.
Most CONS isolates recovered from infants in this study
were resistant to oxacillin and/or gentamicin. Neverthe-
less, similar to Krediet et al's findings [11], we docu-
mented clinical improvement in more than half of the
infants before the initiation of vancomycin, even in the
face of oxacillin resistance. One possible explanation is
that the CONS isolate represented a contaminant rather
than true bacteremia. Although all study patients met the
clinical criteria for sepsis, it is possible that their deterio-
ration was due to other causes. Secondly, the susceptibil-
ity results based on phenotypic testing may indicate
resistance despite the absence of the mecA gene for less
commonly encountered species of CONS (e.g. S. lugdenen-
sis). However, these species are rarely encountered in our
hospital including the NICU, and we have previously
shown that the disk diffusion method for oxacillin suscep-
tibility testing correlates highly with the presence or
absence of the mecA gene [17]. Third, removal of the cen-
tral line may lead to clearance of CONS bacteremia, even
in the absence of antibiotic use. Finally, it may be that the
addition of gentamicin to cloxacillin results in an in vitro
synergistic antibiotic effect on staphylococci [20]. How-
ever, a literature search failed to reveal any published
studies demonstrating such a clinical benefit when
patients are treated with combination therapy for infec-
tions due to CONS isolates that are resistant to oxacillin
in vitro.
This study has several limitations. Although this is one of
the largest studies evaluating outcomes in CONS sepsis in
neonates, we undertook this study as part of a quality
assurance process to compare similar time periods rather
than a pre-determined number of sepsis episodes. Thus,
the sample size limits the strength of our findings. Second,
even with a clear definition of recovery from sepsis, it is
difficult to be certain that sepsis had resolved. Not all
infants had a documented repeat blood culture to confirm
clearance of the organism, therefore duration of sepsis
was recorded in days, rather than hours, which would
have allowed for more precise comparison. We attempted
to minimize this bias by having a single investigator
responsible for assigning duration of sepsis based on a
pre-specified definition for all infants. Third, the use of
historical controls introduces the potential for bias, as
there may be unaccounted for differences between infants
in the two periods that could influence outcome. We
chose comparison periods as close as possible in time to
try to minimize this bias and baseline characteristics of
included infants were similar between periods. A fourth
potential limitation is the use of a single blood culture for
infants exhibiting signs of sepsis. CONS is a frequent con-
taminant and Struthers et al [21] estimated that an addi-
tional 31% of infants were diagnosed as having CONS
sepsis when diagnosis was based on only one blood cul-
ture as compared to two blood cultures. But, more
recently, Sarkar et al [22] found no advantage in drawing
two blood cultures for diagnosing sepsis in 216 neonates.
We tried to limit the number of contaminants by careful
preparation of the skin prior to drawing blood culture,
taking the culture from peripheral sites rather than central
lines, and considering the CONS to be a contaminant if
the isolate was recovered after 48 hours or more of incu-
bation. Furthermore, we included only infants with
simultaneous clinical signs of sepsis. Using these criteria,
six instances of CONS positive blood cultures were
excluded from the study as likely contaminants. A final
potential bias is the presence of a central venous line. Our
data suggests a longer duration of sepsis when a central
line was present, however there is no policy in our unit for
line removal with sepsis. The presence of foreign material
in the bloodstream allows for the formation of biofilm-
incorporating microorganisms, which are very difficult to
treat [23] and can prolong the duration of sepsis [14-16].BMC Pediatrics 2005, 5:49 http://www.biomedcentral.com/1471-2431/5/49
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Reserving vancomycin for the treatment of sepsis caused
by organisms confirmed to be oxacillin resistant is an
important measure to control the spread of vancomycin
resistant organisms. The results of this study suggest that
empiric vancomycin use for late-onset neonatal sepsis
may not be warranted in facilities with a low incidence of
MRSA infections. Although we failed to demonstrate that
a restricted vancomycin policy is not inferior in terms of
duration of sepsis or mortality from CONS sepsis as com-
pared to a non-restricted policy, we observed similar dura-
tion of sepsis (considering that duration estimate can only
be accurate to within 1 day), and mortality was low in
both groups. Given the high incidence but low mortality
and morbidity from CONS sepsis in the NICU, vancomy-
cin could be reserved for episodes of late-onset sepsis in
which the implicated organism is confirmed to be oxacil-
lin resistant. A policy change for empiric treatment of late-
onset sepsis led to an important reduction in vancomycin
use in our NICU. A prospective randomized controlled
trial, powered to adequately assess similar morbidity and
mortality rates is warranted to confirm these findings.
Rubin et al [24] recommend that clinical practice guide-
lines should be developed in NICUs to ensure adequate
blood sampling to decrease contamination, obtaining 2
blood cultures and possibly using adjunctive tests and
information to help differentiate contaminants from
pathogens. These guidelines would assist greatly in con-
ducting such a trial. As well, routinely obtaining repeat
blood cultures to document clearance of the organism
would be helpful in defining length of sepsis and a central
line removal policy would be beneficial in limiting bias
between study groups.
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